1. Home
  2. ENTX vs CHMI Comparison

ENTX vs CHMI Comparison

Compare ENTX & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.24

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Logo Cherry Hill Mortgage Investment Corporation

CHMI

Cherry Hill Mortgage Investment Corporation

HOLD

Current Price

$2.60

Market Cap

97.0M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
CHMI
Founded
2010
2012
Country
Israel
United States
Employees
N/A
14
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
62.6M
97.0M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ENTX
CHMI
Price
$1.24
$2.60
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$10.00
$3.00
AVG Volume (30 Days)
162.1K
203.4K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
15.38%
EPS Growth
N/A
N/A
EPS
0.25
N/A
Revenue
$42,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$61.13
P/E Ratio
$4.76
$139.30
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$2.17
52 Week High
$3.22
$3.14

Technical Indicators

Market Signals
Indicator
ENTX
CHMI
Relative Strength Index (RSI) 49.43 44.97
Support Level $1.17 $2.50
Resistance Level $1.39 $2.76
Average True Range (ATR) 0.12 0.06
MACD 0.02 -0.00
Stochastic Oscillator 41.94 63.33

Price Performance

Historical Comparison
ENTX
CHMI

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

Share on Social Networks: